Clinical Trials Logo

H7N9 Influenza clinical trials

View clinical trials related to H7N9 Influenza.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06417853 Not yet recruiting - H7N9 Influenza Clinical Trials

Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)

HD-MAP
Start date: July 5, 2024
Phase: Phase 1
Study type: Interventional

Study SP-1219-007 is a multi-centre, randomised, study designed to access the safety and tolerability of two doses of monovalent Influenza A (H7N9) vaccine delivered intradermally by a microarray patch delivery system in healthy adults aged 18 to 50 years.

NCT ID: NCT03755427 Not yet recruiting - H7N9 Influenza Clinical Trials

A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine

Start date: November 2018
Phase: Phase 2
Study type: Interventional

The aim of this study is to investigate the immunogenicity and safety of the inactivated whole-virion vaccine for teenagers and adults. The investigators will test the vaccine in participants aged above 12 years, for a randomized, blind, placebo-controlled, clinical study. The investigators designed one dosage groups: 15 μg of hemagglutinin antigen. Control group is designed to inoculate seasonal influence vaccine and aluminum hydroxide adjuvant. Participants will receive 2 doses of vaccine at 21-day intervals. Safety up to 6 months and changes in hemagglutinin inhibition (HI) titers at 21 days after each vaccination will be determined.